One of the modeling studies on breast cancer treatment was the intra-tumoral administration of (CCL21) and interferon γ (IFN-γ) combination to enhance tumor specific T-cell recruitment in the breast cancer microenvironment. This evidence concerns the gene CCL21 and neoplasm.